Holen Sie sich die Stockscreener-App
10.23
0.63%
-0.065
Handel nachbörslich:
10.26
0.025
+0.24%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$10.30
Offen:
$10.42
24-Stunden-Volumen:
2.86M
Relative Volume:
0.59
Marktkapitalisierung:
$1.67B
Einnahmen:
$1.12B
Nettoeinkommen (Verlust:
$440.30M
KGV:
4.2995
EPS:
2.3805
Netto-Cashflow:
$-251.02M
1W Leistung:
+2.56%
1M Leistung:
+17.64%
6M Leistung:
+28.26%
1J Leistung:
+25.28%
1-Tages-Spanne:
$10.12
$10.61
1-Wochen-Bereich:
$9.79
$11.05
52-Wochen-Spanne:
$5.01
$11.97
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
10.23 | 1.68B | 1.12B | 440.30M | -251.02M | 2.3805 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Eingeleitet | Citigroup | Sell |
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
How (NVAX) Movements Inform Risk Allocation Models - Stock Traders Daily
Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026 - Meyka
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform - Investing.com
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability - simplywall.st
Novavax (NASDAQ:NVAX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Novavax Q4 earnings preview: Wall Street expects wider losses amid diversification efforts - MSN
Novavax stock hits over 1-year high: Is Sanofi’s flu-COVID shot the post-pandemic growth driver? - MSN
The 7 Most Hated Stocks on Wall Street Today | Investing - Money/ US News
NVAX: Pivot to platform partnerships and innovation drives growth, with profitability targeted by 2028 - TradingView
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and Statistics - IndexBox
NOVAVAX INC (NASDAQ:NVAX) Screens as a Minervini-Style High-Growth Momentum Candidate - ChartMill
How Investors Are Reacting To Novavax (NVAX) Swinging From Losses To Profits On Vaccine Revenue - simplywall.st
Update Recap: Can Novavax Inc. stock maintain growth trajectory2025 Stock Rankings & High Conviction Trade Alerts - Naître et grandir
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Assessing Novavax (NVAX) Valuation After Strong Earnings Beat And Return To Profitability - simplywall.st
Novavax, Inc. $NVAX Stock Position Lowered by Vanguard Group Inc. - MarketBeat
Novavax at TD Cowen Conference: Strategic Shift to Adjuvant Licensing - Investing.com
Novavax (NVAX) EVP Elaine O'Hara receives major RSU and option grants - Stock Titan
[Form 4] NOVAVAX INC Insider Trading Activity - Stock Titan
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX: Pivoting to a partnership-driven model, the company targets profitability by 2028 with robust pipeline and deals - TradingView
Is Novavax, Inc. (NVAX) a Good Buy at the Moment? - Bitget
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
NVAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Trading Systems Reacting to (NVAX) Volatility - Stock Traders Daily
Sanofi Takes Charge of Novavax COVID Vaccine, Mixed Financial Projections Ahead - StocksToTrade
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-02-28 - Seeking Alpha
Novavax Stock Faces Uncertain Future Amid Low Revenue Guidance - StocksToTrade
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal - Yahoo Finance
How The Novavax (NVAX) Story Is Shifting Toward Licensing Income And COVID Recalibration - Yahoo Finance
Novavax (NASDAQ:NVAX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Trading Down 9.8%Here's What Happened - MarketBeat
Why Novavax (NVAX) Shares Are Falling Today - Finviz
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX) - Seeking Alpha
Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Nasdaq
H.C. Wainwright raises Novavax stock price target on guidance beat - Investing.com
NVAX: HC Wainwright & Co. Raises Price Target Amidst Buy Rating - GuruFocus
NVAX Q4 Deep Dive: Partnership-Led Strategy and Pipeline Transition Shape Outlook - Finviz
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax Q4 Earnings Call Highlights - MarketBeat
Novavax (NASDAQ:NVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPS - MarketBeat
What's Going On With Novavax Stock On Friday? - Bitget
NVV1.F Novavax, Inc. (XETRA) up 15.65% pre-market 27 Feb 2026: earnings catalyst - Meyka
Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novavax Inc-Aktie (NVAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '26 |
Option Exercise |
0.00 |
12,223 |
0 |
136,503 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 03 '26 |
Option Exercise |
0.00 |
43,167 |
0 |
145,130 |
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '26 |
Option Exercise |
0.00 |
58,666 |
0 |
130,299 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
59,600 |
0 |
111,706 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
4,000 |
0 |
65,159 |
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):